About this Research Topic
Hepatobiliary and pancreatic cancers remain as one of the most lethal cancers globally. These cancers continue to have a high mortality rate, poor prognosis and survival rate and overall poor patient outcome due to a poor response rate to treatment. Current forms of treatment include a multimodal approach including surgical treatment, radiation therapy and systemic therapy. There are many areas of research exploring the management of hepatobiliary pancreatic cancer.
Immunotherapy represents an evolving area of research in cancer treatment, and its application in hepatobiliary pancreatic cancers is essential. Areas of immunotherapy utilized in management of hepatobiliary and pancreatic cancers include the latest advancements in checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, examining their clinical efficacy and potential to improve survival rates. Additionally, there is also targeted therapy which focuses on molecular targeted agents and precision medicine approaches based on genetic profiling. These strategies offer the potential to tailor treatments to individual patients, enhancing therapeutic outcomes and minimizing adverse effects.
Combination therapies which integrate immunotherapy and targeted therapy with traditional treatment modalities are also a growing field and option for patients. The synergistic effects of such combinations have shown promise in overcoming resistance and enhancing treatment efficacy. Furthermore, innovations in minimally invasive and robotic surgical techniques are improving surgical outcomes and reducing recovery times for patients. Radiation therapy also continues to evolve with the development of techniques such as stereotactic body radiotherapy (SBRT) and image-guided radiation therapy (IGRT). These innovations are improving the precision and effectiveness of radiation treatment, offering new hope for patients with hepatobiliary pancreatic cancers. In addition, the identification of new biomarkers for early detection and treatment monitoring is critical for improving prognoses.
This Research Topic aims to compile the latest research and clinical insights on these innovative strategies, providing a comprehensive resource for clinicians and researchers dedicated to improving patient outcomes. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Immunotherapy represents an evolving area of research in cancer treatment, and its application in hepatobiliary pancreatic cancers is essential. Areas of immunotherapy utilized in management of hepatobiliary and pancreatic cancers include the latest advancements in checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines, examining their clinical efficacy and potential to improve survival rates. Additionally, there is also targeted therapy which focuses on molecular targeted agents and precision medicine approaches based on genetic profiling. These strategies offer the potential to tailor treatments to individual patients, enhancing therapeutic outcomes and minimizing adverse effects.
Combination therapies which integrate immunotherapy and targeted therapy with traditional treatment modalities are also a growing field and option for patients. The synergistic effects of such combinations have shown promise in overcoming resistance and enhancing treatment efficacy. Furthermore, innovations in minimally invasive and robotic surgical techniques are improving surgical outcomes and reducing recovery times for patients. Radiation therapy also continues to evolve with the development of techniques such as stereotactic body radiotherapy (SBRT) and image-guided radiation therapy (IGRT). These innovations are improving the precision and effectiveness of radiation treatment, offering new hope for patients with hepatobiliary pancreatic cancers. In addition, the identification of new biomarkers for early detection and treatment monitoring is critical for improving prognoses.
This Research Topic aims to compile the latest research and clinical insights on these innovative strategies, providing a comprehensive resource for clinicians and researchers dedicated to improving patient outcomes. We welcome Original Research, Reviews, Systematic Reviews and Mini-Reviews.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases which are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
Keywords: pancreatic cancer, management, hepatobiliary cancer, oncology, cancer, treatment
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
